Literature DB >> 20705433

Regional prefrontal cortex gray matter volumes in youth at familial risk for schizophrenia from the Harvard Adolescent High Risk Study.

Isabelle M Rosso1, Nikos Makris, Heidi W Thermenos, Steven M Hodge, Ariel Brown, David Kennedy, Verne S Caviness, Stephen V Faraone, Ming T Tsuang, Larry J Seidman.   

Abstract

BACKGROUND: Regional prefrontal cortex gray matter reductions have been identified in schizophrenia, likely reflecting a combination of genetic vulnerability and disease effects. Few morphometric studies to date have examined regional prefrontal abnormalities in non-psychotic biological relatives who have not passed through the age range of peak risk for onset of psychosis. We conducted a region-of-interest morphometric study of prefrontal subregions in adolescent and young adult relatives of schizophrenia patients.
METHODS: Twenty-seven familial high-risk (FHR) first-degree relatives of schizophrenia patients and forty-eight control subjects without a family history of psychosis (ages 13-28) underwent high-resolution magnetic resonance imaging at 1.5Tesla. The prefrontal cortex was parcellated into polar, dorsolateral, ventrolateral, ventromedial and orbital subregions. The Chapman scales measured subpsychotic symptoms. General linear models examined associations of prefrontal subregion volumes with familial risk and subpsychotic symptoms.
RESULTS: FHR subjects had significantly reduced bilateral ventromedial prefrontal and frontal pole gray matter volumes compared with controls. Ventromedial volume was significantly negatively correlated with magical ideation and anhedonia scores in FHR subjects.
CONCLUSIONS: Selective, regional prefrontal gray matter reductions may differentially mark genetic vulnerability and early symptom processes among non-psychotic young adults at familial risk for schizophrenia.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20705433      PMCID: PMC2939267          DOI: 10.1016/j.schres.2010.06.015

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  54 in total

1.  Altered brain activation in dorsolateral prefrontal cortex in adolescents and young adults at genetic risk for schizophrenia: an fMRI study of working memory.

Authors:  Larry J Seidman; Heidi W Thermenos; Russell A Poldrack; Nicole K Peace; Jennifer K Koch; Stephen V Faraone; Ming T Tsuang
Journal:  Schizophr Res       Date:  2006-04-24       Impact factor: 4.939

2.  Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia.

Authors:  Nicole R Giuliani; Vince D Calhoun; Godfrey D Pearlson; Alan Francis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2005-05-01       Impact factor: 4.939

3.  Genetically predisposed offspring with schizotypal features: an ultra high-risk group for schizophrenia?

Authors:  Vaibhav A Diwadkar; Debra M Montrose; Diana Dworakowski; John A Sweeney; Matcheri S Keshavan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-11-28       Impact factor: 5.067

4.  Gray and white matter density changes in monozygotic and same-sex dizygotic twins discordant for schizophrenia using voxel-based morphometry.

Authors:  Hilleke E Hulshoff Pol; Hugo G Schnack; René C W Mandl; Rachel G H Brans; Neeltje E M van Haren; Wim F C Baaré; Clarine J van Oel; D Louis Collins; Alan C Evans; René S Kahn
Journal:  Neuroimage       Date:  2006-02-23       Impact factor: 6.556

5.  Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure.

Authors:  Andrew M McIntosh; Dominic E Job; William J Moorhead; Lesley K Harrison; Heather C Whalley; Eve C Johnstone; Stephen M Lawrie
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-01-05       Impact factor: 3.568

Review 6.  Brain maturational processes and delayed onset in schizophrenia.

Authors:  M S Keshavan; G E Hogarty
Journal:  Dev Psychopathol       Date:  1999

7.  Body-image aberration in Schizophrenia.

Authors:  L J Chapman; J P Chapman; M L Raulin
Journal:  J Abnorm Psychol       Date:  1978-08

8.  Human cerebral cortex: localization, parcellation, and morphometry with magnetic resonance imaging.

Authors:  J Rademacher; A M Galaburda; D N Kennedy; P A Filipek; V S Caviness
Journal:  J Cogn Neurosci       Date:  1992       Impact factor: 3.225

9.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

10.  The validity of Psychosis Proneness Scales as vulnerability indicators in recent-onset schizophrenia patients.

Authors:  William P Horan; Steven P Reise; Kenneth L Subotnik; Joseph Ventura; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2008-01-24       Impact factor: 4.939

View more
  19 in total

1.  Examining Specificity of Neural Correlates of Childhood Psychotic-like Experiences During an Emotional n-Back Task.

Authors:  Kathleen J O'Brien; Deanna M Barch; Sridhar Kandala; Nicole R Karcher
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-03-19

Review 2.  Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings.

Authors:  Benjamin K Brent; Heidi W Thermenos; Matcheri S Keshavan; Larry J Seidman
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-07-23

3.  Disease and genetic contributions toward local tissue volume disturbances in schizophrenia: a tensor-based morphometry study.

Authors:  Yaling Yang; Keith H Nuechterlein; Owen R Phillips; Boris Gutman; Florian Kurth; Ivo Dinov; Paul M Thompson; Robert F Asarnow; Arthur W Toga; Katherine L Narr
Journal:  Hum Brain Mapp       Date:  2012-09       Impact factor: 5.038

4.  Early and broadly defined psychosis risk mental states.

Authors:  Matcheri S Keshavan; Lynn E DeLisi; Larry J Seidman
Journal:  Schizophr Res       Date:  2010-11-30       Impact factor: 4.939

5.  Are we studying and treating schizophrenia correctly?

Authors:  Neal R Swerdlow
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

6.  Familial and environmental influences on brain volumes in twins with schizophrenia.

Authors:  Marco M Picchioni; Fruhling Rijsdijk; Timothea Toulopoulou; Christopher Chaddock; James H Cole; Ulrich Ettinger; Ana Oses; Hugo Metcalfe; Robin M Murray; Philip McGuire
Journal:  J Psychiatry Neurosci       Date:  2017-03       Impact factor: 6.186

7.  Executive functioning and psychopathological profile in relatives of individuals with deficit v. non-deficit schizophrenia: a pilot study.

Authors:  S Scala; A Lasalvia; L J Seidman; D Cristofalo; C Bonetto; M Ruggeri
Journal:  Epidemiol Psychiatr Sci       Date:  2013-04-02       Impact factor: 6.892

8.  Alterations of lateral temporal cortical gray matter and facial memory as vulnerability indicators for schizophrenia: An MRI study in youth at familial high-risk for schizophrenia.

Authors:  Benjamin K Brent; Isabelle M Rosso; Heidi W Thermenos; Daphne J Holt; Stephen V Faraone; Nikos Makris; Ming T Tsuang; Larry J Seidman
Journal:  Schizophr Res       Date:  2015-11-24       Impact factor: 4.939

9.  Alterations in brain structures underlying language function in young adults at high familial risk for schizophrenia.

Authors:  Alan N Francis; Larry J Seidman; Gul A Jabbar; Raquelle Mesholam-Gately; Heidi W Thermenos; Richard Juelich; Ashley C Proal; Martha Shenton; Marek Kubicki; Ian Mathew; Matcheri Keshavan; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-08-11       Impact factor: 4.939

10.  Relationship between prefrontal gray matter volumes and working memory performance in schizophrenia: a family study.

Authors:  Vina M Goghari; Angus W Macdonald; Scott R Sponheim
Journal:  Schizophr Res       Date:  2014-02-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.